Why Exact Sciences Stock Plunged in 2021
Shares of medical diagnostic company Exact Sciences (NASDAQ: EXAS) fell by a jaw-dropping 41% over the whole of 2021, according to data provided by S&P Global Market Intelligence. Although the novel cancer diagnostic company saw a healthy rise in sales last year, and this sales growth is widely expected to continue in 2022, Exact's staggering losses haven't been sitting well with shareholders of late.
During the first nine months of 2021, for instance, Exact lost a noteworthy $634 million. What's more, the company is on track to remain cash flow negative for the foreseeable future.
Image source: Getty Images.
Source Fool.com
